Skip to main content
. 2025 Jan 20;15(1):64. doi: 10.3390/metabo15010064

Figure 1.

Figure 1

Comparison of plasma phenylacetylglutamine (PAGln) levels among patients with MACEs and non-MACEs. (a) Scatter plot shows circulating PAGln concentration in patients with hypertension who experienced MACEs compared with non-MACEs in the discovery cohort. (b) Scatter plot shows circulating PAGln concentration in patients with hypertension who experienced MACEs compared with non-MACEs in the validation cohort. The filled red circles represent patients with MACEs and the filled black circles represent patients with non-MACEs. The central line represents the median, the rectangles give the interval between the first and third quartiles. p Values were calculated using Mann–Whitney U test.